Recap: Wesbanco Q4 Earnings

Wesbanco (NASDAQ:WSBC) reported its Q4 earnings results on Tuesday, January 23, 2024 at 04:15 PM. Here’s what investors…

Wesbanco (NASDAQ:WSBC) reported its Q4 earnings results on Tuesday, January 23, 2024 at 04:15 PM.

Here’s what investors need to know about the announcement.

Earnings

Wesbanco missed estimated earnings by 1.79%, reporting an EPS of $0.55 versus an estimate of $0.56.

Revenue was down $12.12 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0 which was followed by a 2.68% increase in the share price the next day.

Here’s a look at Wesbanco’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 0.59 0.66 0.77 0.83
EPS Actual 0.59 0.71 0.71 0.84
Revenue Estimate 122.47M 122.89M 132.78M 129.98M
Revenue Actual 117.68M 121.57M 124.33M 129.87M

To track all earnings releases for Wesbanco visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Analysts’ Varied Perspectives On CytomX’s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.

CTMX